Cell therapy companies face many hurdles. I wrote recently about four cell therapy biotechs that have been really struggling. Blogging here at The Niche for more than a dozen years, I’ve seen many companies even go under. That’s bad news for the field, for patients, and for investors. Today I wanted to highlight some cell therapy […]
3 cell therapy companies doing well: Vertex, Vericel, & Regeneron Read More »
The Bay Area biotech Conception Bio has an intriguing name. What does “conception” mean here? Scientists can make many things from stem cells. For example, lately I’ve written a lot about stem cell-based human embryo models. Another intriguing area is called in vitro gametogenesis or IVG, where Conception Bio is a leader. IVG means making
Weekly reads: Conception Bio & IVG, MYC, Stanford Prez resigns Read More »
I’m kind of in grant writing hell at the moment, as many of you may have been at various times, but I’m still finding time to read a little on cell therapy and stem cell research. Here are some things that caught my eye as I work on multiple grants with impending deadlines. Clinical trials
Weekly reads: cell therapy trials, melanoma, β-thalassemia Read More »
Where do things stand with potential applications of CRISPR and other gene editing technologies in patients? Overall, things are looking very positive. CRISPR human trials This week the third big international human genome editing meeting took place in London. The summit addressed numerous potential clinical applications. It was good to see the agenda included quite
Weekly reads: big CRISPR mtg, Mesoblast good news, Neuralink spiked Read More »
I had heard that we might see criminal charges or convictions in 2022 for unproven stem cell clinic activities. This led to my prediction for last year of a criminal conviction in the stem cell clinic sphere. The prediction was correct as a Florida man selling unproven stem cell injections was been sentenced in late December
Stem cell clinic ‘doc’ sentenced to 202 years in prison Read More »
Let’s start with some stem cell good news on evolving approaches to treat sickle cell disease involving stem cells. Then on another related front things were more concerning. Stem cell good news on sickle cell disease, a complication Sickle Cell Disease News reports Adding Briquilimab Boosts Success of Sickle Cell Stem Cell Transplant. This is a
Weekly reads: stem cell good news, bad news on sickle cell, MS, IPSCs Read More »
The big news of the week was the launch of Altos labs and their ambitious plan to tackle aging through cell therapies. Altos has recruited a large number of top cell biologists away from academia. That team plus top biotech execs and a $3B war chest make Altos one to watch in coming years. I
Weekly reads: aging, CRISPR delivery, hair, oocytes, paralysis Read More »
Is 2022 going to be any better than 2020 or 2021 when it comes to things in general or for biomedical science? Related to the pandemic? It’s too soon to say but if I had to guess right now I’d venture an optimistic view that overall it’s going to be somewhat better by the end
Weekly science reads: senescence, alt CRISPR, sickle cell update Read More »
Happy New Year and get ready for another 364 more days of stem cell excitement and craziness in 2022. In the next day or two I’ll post my predictions for this new year. Recommended reads EO Wilson obit by Carl Zimmer in NYT. Who’s the next EO Wilson or someone like him with such big impact these
Weekly stem cell reads: COVID kidney, FDA letter, H3.3, EO Wilson Read More »
The past year was all over the place for the stem cell and regenerative medicine field. As you can see in my scoring of my 21 predictions for 2021, quite a few things were surprises in terms of what did and didn’t happen. Here’s an overview of the top stories of the year in our
Top stem cell stories of 2021: COVID, diabetes, human embryos, clinics in court Read More »